TY - DATA T1 - 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Analysis of the Randomized, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension PY - 2018/09/07 AU - Hirofumi Ochi AU - Masaaki Niino AU - Yasuhiro Onizuka AU - Katsutoshi Hiramatsu AU - Masakazu Hase AU - Jang Yun AU - André Matta AU - Shinichi Torii UR - https://adisjournals.figshare.com/articles/figure/72-Week_Safety_and_Tolerability_of_Dimethyl_Fumarate_in_Japanese_Patients_with_Relapsing-Remitting_Multiple_Sclerosis_Analysis_of_the_Randomized_Double_Blind_Placebo-Controlled_Phase_III_APEX_Study_and_its_Open-Label_Extension/7028819 DO - 10.6084/m9.figshare.7028819.v1 L4 - https://ndownloader.figshare.com/files/12918272 KW - APEX KW - Dimethyl fumarate KW - Japanese KW - Neurology KW - Phase 3 KW - Relapsing-remitting multiple sclerosis KW - Safety N2 - Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides ER -